NRG1 and schizophrenia: Future investigations should attempt to account for these other signaling factors and the potential confounders of metabolic changes in people with schizophrenia being treated with clozapine, as doing so will further elucidate the suitability of P70S6K as a peripheral biomarker of over-activity in the NRG1 pathway in schizophrenia.